Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enteral versus intravenous phosphate replacement for hypophosphatemia in ICU adults
ACTRN12622000533796Phase 4Completed
- Sponsor
- Royal Melbourne Hospital
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of phosphate, sodium phosphate monobasic and potassium dihydrogen phosphate in hypophosphatemia (2 arms), sponsored by Royal Melbourne Hospital. Primary endpoint: Change in serum phosphate at 24 hours. Started Apr 2022; status: completed.
02
Drugs
phosphatesodium phosphate monobasicpotassium dihydrogen phosphate
03
Conditions
hypophosphatemia
Beyond the preview
Go deeper on ACTRN12622000533796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12622000533796.